Trial achieved its primary endpoint of pathological Complete Response Rate Trial achieved its secondary endpoint in operability (R0 rate) NBTXR3 demonstrated significant superiority and clinical …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
